Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vyndaqel
Pharma
Look out, Pfizer: BridgeBio gains 'best-case' FDA nod for Attruby
The FDA has approved BridgeBio's Attruby to treat cardiomyopathy. With the nod, BridgeBio will challenge Pfizer’s powerhouse Vyndaqel franchise.
Kevin Dunleavy
Nov 25, 2024 7:59am
Pfizer's ATTR drug again faces pricing scrutiny
Oct 21, 2024 2:55pm
Alnylam sees Amvuttra as potential standard of care in ATTR-CM
Aug 30, 2024 10:06am
Pfizer's ATTR drug needs hefty discount, says ICER draft report
Jul 18, 2024 4:37pm
Alnylam touts 'big-win scenario' for closely watched heart trial
Jun 24, 2024 10:53am
Experts paint tough path ahead of Alnylam's key ATTR-CM readout
Apr 22, 2024 10:55am
